Clinical Trials Logo

TCC clinical trials

View clinical trials related to TCC.

Filter by:
  • None
  • Page 1

NCT ID: NCT04671407 Recruiting - TCC Clinical Trials

The Aim of This Study is to Compare the Efficacy of Perioperative Hypertonic Saline 3% Versus Normal Saline (0.9%) in Decreasing Recurrence Risk in Non-muscle Invasive Bladder Cancer

Start date: January 20, 2021
Phase: Phase 2
Study type: Interventional

Purpose: to demonstrate a 10% recurrence risk reduction for patients treated with Hypersal versus normal saline immediately following TURBT. Design: prospective randomized double-blind placebo controlled trial. Outline: eligible patients with non-muscle invasive bladder cancer who undergo TURBT at our center will be randomized to receive either 40ml of normal saline or 40 ml of hypersal intravesically. The primary endpoint is tumor recurrence rate. Secondary endpoint are time to recurrence and side effects. Patients A total of 150 patients will be enrolled in this trial.

NCT ID: NCT04147182 Active, not recruiting - TCC Clinical Trials

Perioperative Intravesical Instilation of Hypertonic Saline Following Bladder Tumor Resection

Start date: December 2, 2018
Phase: Phase 1
Study type: Interventional

Hypertonic saline at the concentration of 3% (hypersel) has been injected for years into echinococcal cysts to kill live scolices, and is also known to kill suspended cells by means of a steep osmotic gradient and the investigators postulate that perioperative intravesical instillation of hypersel for patients with low grade bladder cancer is safe and may be active against shedded and suspended tumor cells and thus may decrease recurrence risk.